The burgeoning landscape of treatment for weight management and type 2 glucose intolerance is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant distinctions in their pharmacological profiles and clinical investigation results are eme… Read More

Arriving in the arena of weight management treatment, retatrutide represents a different approach. Beyond many existing medications, retatrutide functions as a twin agonist, simultaneously engaging both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic substance (GIP) binding sites. The concurrent activation fosters several beneficial e… Read More